Earnings PowerManagement expressed confidence in the company's earnings power and its ability to withstand competition.
Financial PerformanceActivity-related fee income remained elevated, which supports strong financial performance.
Investment GainsTSLX is likely to recognize a gain from its Aug. 7, 2024 investment in Arrowhead Pharmaceuticals, as the company announced a licensing and collaboration agreement that will likely result in a positive outcome.